SV2B Activators
SV2B activators constitute a class of chemicals that target and modulate the activity of the synaptic vesicle glycoprotein 2B (SV2B). SV2B is one of the proteins in the SV2 family, which plays a crucial role in the regulation of neurotransmitter release at synaptic junctions. The protein is believed to be involved in the formation or maintenance of synaptic vesicle pools and may influence the efficiency of synaptic transmission through its interactions with other synaptic proteins.
Direct activators of SV2B interact with the protein to enhance its function, potentially by stabilizing the protein structure, facilitating its interaction with other synaptic proteins, or by promoting a conformational change that increases its activity in neurotransmitter release. Such activators might bind to specific domains of SV2B, leading to an increase in the readiness of synaptic vesicles for exocytosis or by improving the coupling between electrical activity and neurotransmitter release. Indirect activators might work by influencing the expression levels of the SV2B gene, thereby increasing the amount of protein available at synaptic sites. Other indirect mechanisms could involve the modification of the SV2B protein post-translationally, such as by phosphorylation, to enhance its activity or by affecting the lipid environment of synaptic vesicles, which could alter SV2B function. Additionally, indirect activators could modulate the interaction of SV2B with other proteins critical for neurotransmitter release, thereby enhancing its role in the synaptic machinery.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Veratridine | 71-62-5 | sc-201075B sc-201075 sc-201075C sc-201075A | 5 mg 10 mg 25 mg 50 mg | $82.00 $104.00 $201.00 $379.00 | 3 | |
Veratridine is a steroidal alkaloid that acts as a Na+ channel modulator, causing a persistent sodium influx. This continuous influx can result in enhanced synaptic vesicle release, including SV2B-containing vesicles. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is a calcium channel blocker. By inhibiting these channels, it increases the demand for compensatory mechanisms in neurotransmitter release, potentially causing an increased release of SV2B-containing vesicles. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of vacuolar-type H+-ATPase. By inhibiting this pump, it disrupts the acidic environment of synaptic vesicles, potentially leading to an increased release of SV2B-containing vesicles. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an activator of adenylate cyclase, which increases intracellular cAMP levels. The raised cAMP can activate Protein Kinase A, which can enhance synaptic vesicle exocytosis, including SV2B-containing vesicles. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of Protein Kinase C (PKC). PKC can enhance synaptic vesicle exocytosis, including SV2B-containing vesicles. | ||||||
Tetraethylammonium chloride | 56-34-8 | sc-202834 | 25 g | $45.00 | 2 | |
TEA is a potassium channel blocker, resulting in prolonged action potentials. This can lead to enhanced synaptic vesicle release, including SV2B-containing vesicles. | ||||||
4-Aminopyridine | 504-24-5 | sc-202421 sc-202421B sc-202421A | 25 g 1 kg 100 g | $38.00 $1155.00 $122.00 | 3 | |
4-AP is a potassium channel blocker, leading to prolonged action potentials. This can result in enhanced synaptic vesicle release, including SV2B-containing vesicles. | ||||||
Reserpine | 50-55-5 | sc-203370 sc-203370A | 1 g 5 g | $137.00 $414.00 | 1 | |
Reserpine depletes monoamines from synaptic vesicles, disrupting vesicle homeostasis and potentially leading to an increased release of SV2B-containing vesicles. | ||||||
Ethosuximide | 77-67-8 | sc-211431 | 1 g | $306.00 | ||
Ethosuximide is a T-type calcium channel blocker. By blocking these channels, it increases the demand for compensatory mechanisms in neurotransmitter release, potentially causing an increased release of SV2B-containing vesicles. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a PDE1 inhibitor, leading to increased cAMP/cGMP levels. The increased cAMP can activate PKA, which can enhance synaptic vesicle exocytosis, including SV2B-containing vesicles. | ||||||